This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
What to Expect from Endocyte (ECYT) Stock for Q1 Earnings?
by Zacks Equity Research
Endocyte, Inc (ECYT) is expected to report first-quarter 2017 results on May 3.
Endocyte (ECYT) Up 3.5% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Endocyte (ECYT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
5 Cheap Breakout Stocks for Superb Returns
by Swarup Gupta
The technique identifies those stocks whose prices are fluctuating within a specific band.
Endocyte (ECYT) Reports Wider-than-Expected Loss in Q4
by Zacks Equity Research
Endocyte, Inc. (ECYT) reported a fourth-quarter 2016 loss of 26 cents per share, wider than both the Zacks Consensus Estimate of a loss of 25 cents and the year-ago loss of 23 cents.
Endocyte (ECYT) Shares March Higher, Can It Continue?
by Zacks Equity Research
Endocyte, Inc. (ECYT) has been on the move lately as the stock has risen by 20.2% in the past four weeks, and it is currently trading well above its 20-Day SMA
Endocyte (ECYT) Reports a Wider Q4 Loss
by Zacks Equity Research
Endocyte reported a loss per share of 26 cents per share while our consensus called for a loss of 25 cents per share.
Endocyte (ECYT) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Endocyte, Inc (ECYT) is expected to report fourth-quarter 2016 results on Mar 1. The company has an impressive track record, having beaten estimates on three of the trailing four quarters and reporting in-line results in the remaining quarter
Valeant Streamlines Portfolio with Skincare Brands Sale
by Zacks Equity Research
Beleaguered Valeant Pharmaceuticals International, Inc. (VRX) announced that it has entered into an agreement to sell its CeraVe, AcneFree and AMBI skincare brands to L'Or??al for $1.3 billion in cash.
Valeant to Sell Dendreon Unit to Sanpower for $820 Million
by Zacks Equity Research
Beleaguered Valeant Pharmaceuticals International, Inc. (VRX) announced that it will sell all the outstanding equity interests in Dendreon Pharmaceuticals, Inc. to the China based Sanpower Group Co., Ltd.
Is Valeant (VRX) Fated for Terrible 2017 As Well?
by Zacks Equity Research
Shares of Valeant Pharmaceuticals, Inc. (VRX) slumped 85.3% in 2016, eroding a chunk of shareholders' net worth.